Author: Kwang Su Kim; Keisuke Ejima; Yusuke Ito; Shoya Iwanami; Hirofumi Ohashi; Yoshiki Koizumi; Yusuke Asai; Shinji Nakaoka; Koichi Watashi; Robin N Thompson; Shingo Iwami
Title: Modelling SARS-CoV-2 Dynamics: Implications for Therapy Document date: 2020_3_27
ID: 09r4d3nu_12
Snippet: The majority of antiviral drugs inhibit intracellular virus replication. Although 159 their antiviral efficacies need to be confirmed, lopinavir/ritonavir (HIV protease 160 inhibitors), remdesivir (anti-Ebola virus disease candidate) and other nucleoside 161 analogues, and interferon have the potential to suppress SARS-CoV-2 by blocking 162 virus production (15, 16) . Interestingly, our results suggest that, even for relatively 163 small inhibiti.....
Document: The majority of antiviral drugs inhibit intracellular virus replication. Although 159 their antiviral efficacies need to be confirmed, lopinavir/ritonavir (HIV protease 160 inhibitors), remdesivir (anti-Ebola virus disease candidate) and other nucleoside 161 analogues, and interferon have the potential to suppress SARS-CoV-2 by blocking 162 virus production (15, 16) . Interestingly, our results suggest that, even for relatively 163 small inhibition rates of around 30%, the AUC of viral load is partially reduced if 164 therapy is initiated early (within three days after symptom onset) (Fig. 3BE) . 165
Search related documents:
Co phrase search for related documents- antiviral drug and inhibition rate: 1
- antiviral drug and intracellular virus: 1, 2, 3, 4
- antiviral drug and intracellular virus replication: 1
- antiviral drug and partially reduce: 1
- antiviral drug and SARS suppress: 1, 2, 3, 4, 5, 6
- antiviral drug and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antiviral drug and viral load: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral drug and virus disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- antiviral drug and virus production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- antiviral efficacy and HIV protease: 1, 2, 3
- antiviral efficacy and inhibition rate: 1
- antiviral efficacy and intracellular virus: 1, 2
- antiviral efficacy and intracellular virus replication: 1
- antiviral efficacy and SARS suppress: 1, 2, 3, 4
- antiviral efficacy and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antiviral efficacy and viral load: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- antiviral efficacy and viral load auc: 1
- antiviral efficacy and virus disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- antiviral efficacy and virus production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Co phrase search for related documents, hyperlinks ordered by date